Business
Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026
Highlighting Optimized Once-Daily Weight-Based Dosing and Clinically Meaningful Fatigue Improveme...
About this update from Thiogenesis Therapeutics Corp
[{"type":"text","content":"Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026Highlighting Optimized Once-Daily Weight-Based Dosing and Clinically Meaningful Fatigue ImprovementSan Diego, California--(Newsfile Corp. - January 23, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (\"Thiogenesis\" or the \"Company\"), a clinical-stage biotechnology company developing next-generation thiol-based prodrugs for rare mitochondrial and pediatric diseases, today announced the presentation of interim data from its Phase 2 (EU) clinical study of TTI-0102 in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) at Mitocon 2026 - a leading international conference dedicated to mitochondrial medicine being held in Pisa, Italy.The poster, titled \"TTI-0102 in MELAS: PK/PD Results from a Phase 2 Study - Preliminary Evidence of Safety and Efficacy in Mitochondrial Disease,\" was presented on January 23 as part of Mitocon's Late-Breaking News session, a distinction reserved for data of high scientific and clinical relevance selected by the conference's Scientific Committee.Phase 2 (EU) MELAS - Study HighlightsThe randomized, single-blind, high fixed-dose, placebo-controlled exploratory Phase 2 (EU) study enrolled nine (n=9) patients with genetically confirmed MELAS, a devastating mitochondrial disorder with limited therapeutic options. Results presented at Mitocon demonstrated that weight-based dosing is critical to achieving optimal exposure and tolerability, consistent with long-standing clinical experience using cysteamine in concentrations comparable to approved formulations (Cystagon® or Procysbi®) in cystinosis.Key clinical, pharmacokinetic, and pharmacodynamic findings included:Clinical Outcome (Fatigue):Statistically significant improvement in patient-reported fatigue as measured by the total score of Modified Fatigue Impact Scale (MFIS)At an average dose of approximately 60 mg/kg/day, TTI-0102-treated patients demonstrated a mean reduction of up to 10% in total MFIS score compared to placebo (p < 0.001)Fatigue is a cardinal and functionally limiting symptom affecting patients with mitochondrial diseasePharmacokinetics (PK):Sustained 24-hour cysteamine exposure achieved with once-daily, weight-based dosingIdentification of an optimal dose of approximately 60 ± 5 mg/kg of TTI-0102...